INNOVATE
Strategic Objectives
R&D-led diversification and integrated offerings
Investment in disruptive innovation
Advancing new technology platforms
Digitisation and automation
Progress during FY 2025-26
Accelerated involvement in key clinical and commercial integrated programs with innovator partner
Sustained global market leadership in ARV
Progressed capabilities in peptides, ADC and gene therapy, including continued build-out of related development and manufacturing infrastructure
Invested in Aarvik Therapeutics, an ADC platform company
ImmunoACT partnered with Cipla to launch NexCAR-19 in Africa and initiated Phase 1 BCMA-CT
Advanced technology platforms such as biocatalysis, flow chemistry and continuous manufacturing across mid- and late-stage clinical projects and commercial-stage projects
Achieved ISO 27001:2022 certification, reinforcing the Company's information security framework
EXCEL
Strategic Objectives
Strong product portfolio and customer-centric approach
Operational excellence and regulatory compliance
Talent development and leadership culture
Progress during FY 2025-26
Maintained a healthy CDMO pipeline with 125+ active projects across clinical and commercial stages
Advanced the developed market FDF portfolio, with 7 dossiers filed and 6 approvals received during the year
Supported 94 R&D projects (DS/DP) during the year
Delivered continued growth across CDMO and Affordable Medicines, supported by commercial deliveries, volume growth and improving operating leverage
Maintained a strong quality track record, with 132+ quality audits completed during the year without critical findings
Continued to strengthen the team to support expanded facilities and new capabilities, while investing in people, process and leadership for scale-up and execution
Installed advanced foam tender systems across manufacturing sites
Completed career development reviews for 100% of employees
Continued to operate with a "one quality standard for all markets" approach across the manufacturing network
EXPAND
Strategic Objectives
Large-scale manufacturing and R&D infrastructure
Market and customer base expansion
Leveraging technology synergies
Sustainable growth and value creation
Progress during FY 2025-26
Continued capex-led expansion across manufacturing and R&D, with investments of ~16% of revenue during the year
Progressed key projects including small molecules APIs, microbial fermentation capacity, oral dosage expansion at Vizag, and Gene therapy/ADC capabilities
Secured 532 acres of land in Andhra Pradesh to support development of a future integrated manufacturing complex
Continued expansion of customer-aligned capacity across CDMO and Affordable Medicines to support future growth and utilisation visibility
Maintained an outstanding track record in EHS systems
Achieved an S&P Global ESG score of 81/100 points, reflecting a 10 points improvement over the previous year